RCC

CANADIAN NON-PROFIT OFFERS FREE ACCESS TO THEIR SUPPORT PATHS FOR BLACK FOOD ENTREPRENEURS.

Retrieved on: 
Friday, February 9, 2024
RCC, Government, Government of Canada, Favourite Things, Canadian Grand Prix, Black, Food, Map, BIPOC, Greater Toronto Area

Now in its fourth year, the Advisor-Led Start and Scale Support Path project provides free access to industry experts ranging from accountants and branding professionals to chefs and food scientists throughout its guided nine-month program.

Key Points: 
  • Now in its fourth year, the Advisor-Led Start and Scale Support Path project provides free access to industry experts ranging from accountants and branding professionals to chefs and food scientists throughout its guided nine-month program.
  • More than a traditional incubator accelerator, the paths focus on removing systemic barriers, increasing access, forging community and centring the lived experience of BIPOC individuals.
  • ‘It is through food that communities connect and foster a sense of belonging,’ says Foodpreneur Lab founder Janice Bartley.
  • ‘The network, the experience, and the results have all been amazing,’ says Start Support Path participant Robert Robinson of Robinson Sauces.

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Molecule, Royalty payment, Conference, Liver disease, Calendar, Breast, Immunotherapy, RCC, PIN, ASCO, NHT, Progression-free survival, Safety, FDA, PLK4, ADC, ITT, PKMYT1, Associate, University, Baylor University, PARP, USP1, Society, Neck, Science, Acquisition, Biology, Superior, Huntsman Cancer Institute, Dean (education), Metastasis, PFS, Translational research, Drug development, Distinguishing, Head, Food, NET, Baylor College of Medicine, Cancer, Share repurchase, BIRC, OS, SCCHN, Neoplasm, Congress, National Cancer Institute, Abbreviated New Drug Application, Research, Docetaxel, Translation, Prostate cancer, Therapy, ESMO, Education, Experiment, Checkmate, Pharmaceutical industry

In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion.

Key Points: 
  • In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion.
  • Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter and year ended December 31, 2023, Exelixis earned $40.7 million and $148.5 million, respectively, in royalty revenues.
  • In October 2023, detailed results were presented from the phase 3 CABINET pivotal trial at the 2023 ESMO Congress.
  • Exelixis management will discuss the company’s financial results for the fourth quarter and fiscal year of 2023 and provide a general business update during a conference call beginning at 5:00 p.m.

AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist

Retrieved on: 
Tuesday, February 6, 2024
OS, Vanderbilt-Ingram Cancer Center, VEGFR, Survival, IO, TKI, Renal cell carcinoma, Division, RCC, MD, PFS, Safety, Patient, Progression-free survival, Sorafenib, Arm, Disease, ITT, Assistant, Oncology, LG Chem, Doctor of Philosophy, Pharmaceutical industry

The trial included a predefined subgroup of patients (26%) who were previously treated with both an immuno-oncology (IO) therapy and a VEGFR TKI.

Key Points: 
  • The trial included a predefined subgroup of patients (26%) who were previously treated with both an immuno-oncology (IO) therapy and a VEGFR TKI.
  • “For patients with relapsed or refractory advanced renal cell carcinoma, long-term progression-free survival is a vital measure of the value of anticancer therapy,” commented Michael Bailey, President and CEO of AVEO Oncology.
  • The trial randomized 350 patients to receive FOTIVDA (1.5 mg once daily) or sorafenib (400 mg twice daily).
  • The intent-to-treat (ITT) population included 175 patients in each arm; the safety population included 173 patients in the FOTIVDA arm and 170 in the sorafenib arm.

Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Retrieved on: 
Tuesday, February 6, 2024
RCC, Idiopathic pulmonary fibrosis, Therapy, Patient, Chronic cough, Webcast, IPF, Conference, News

NEW HAVEN, Conn., Feb. 6, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, will be presenting at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, at 10:00 a.m. ET. During this virtual event, Ms. Good along with Lisa Delfini, Chief Financial Officer, will also participate in investor meetings with attendees.  

Key Points: 
  • ET
    NEW HAVEN, Conn., Feb. 6, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, will be presenting at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, at 10:00 a.m.
  • During this virtual event, Ms. Good along with Lisa Delfini, Chief Financial Officer, will also participate in investor meetings with attendees.
  • A live webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com .
  • An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy

Retrieved on: 
Saturday, January 27, 2024
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, MSD, Dana–Farber Cancer Institute, Renal cell carcinoma, Death, VEGF, Patient, M1, OS, RCC, Harvard Medical School, ASCO, Survival, DFS, Medicine, Society, NED, Cancer, Nephrectomy, Kidney, Risk, Recurrence, Disease, Safety, Eisai, Merck & Co., CPS, Rated R, MRK, Pharmaceutical industry

At 48 months, the estimated OS rate was 91.2% for patients who received KEYTRUDA compared to 86.0% for patients who received placebo.

Key Points: 
  • At 48 months, the estimated OS rate was 91.2% for patients who received KEYTRUDA compared to 86.0% for patients who received placebo.
  • Treatment-related adverse events (TRAEs) occurred in 79.1% of patients (n=386) in the KEYTRUDA arm and 53.0% of patients (n=263) in the placebo arm.
  • Grade 3-4 TRAEs occurred in 18.6% of patients in the KEYTRUDA arm and 1.2% of patients in the placebo arm.
  • Treatment-related adverse events resulting in discontinuation of any treatment occurred in 18.2% of patients in the KEYTRUDA arm and 0.8% of patients in the placebo arm.

First Patient Dosed in Phase 2 Portion of Aulos Bioscience’s Phase 1/2 Clinical Trial for AU-007, a Computationally Designed IL-2 Antibody for Solid Tumor Cancers

Retrieved on: 
Thursday, January 25, 2024
Oncology, Health, Technology, Clinical Trials, Artificial Intelligence, Pharmaceutical, Biotechnology, NK, Immunoglobulin G, Renal cell carcinoma, Neoplasm, Patient, Kidney, Melanoma, Neck, RCC, CD25, Interleukin, Head, Safety, Eosinophil, Therapy, Clinical trial, Cell, Immune system, Vaccine

AU-007 is a human IgG1 monoclonal antibody designed to harness the power of interleukin-2 (IL-2) to eradicate solid tumors, and the first AI-designed human monoclonal antibody to be tested in a clinical trial.

Key Points: 
  • AU-007 is a human IgG1 monoclonal antibody designed to harness the power of interleukin-2 (IL-2) to eradicate solid tumors, and the first AI-designed human monoclonal antibody to be tested in a clinical trial.
  • Phase 1 data demonstrate that AU-007 is currently the only IL-2 agent that can reduce regulatory T cells (Tregs), which suppress the immune system.
  • This redirects IL-2 to medium-affinity receptors on effector T cells (Teffs) and natural killer (NK) cells, which expand and kill tumor cells.
  • To learn more about the AU-007 clinical trial program, please visit ClinicalTrials.gov (identifier: NCT05267626 ).

Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Retrieved on: 
Monday, January 22, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Bristol Myers Squibb, Death, Checkmate, Patient, Progression-free survival, OS, RCC, ASCO, Survival, Nivolumab, Ipilimumab, IRRC, Society, Risk, Immunotherapy, MD Anderson Cancer Center, Division, PFS, Abstract, Safety, Confidence interval, University, BMY, Sunitinib, IMDC, ITT

Patients treated with Opdivo plus Yervoy maintained superior survival and more durable response benefits compared to those who received sunitinib in both patients with intermediate- and poor-risk prognostic factors and across all randomized patients.

Key Points: 
  • Patients treated with Opdivo plus Yervoy maintained superior survival and more durable response benefits compared to those who received sunitinib in both patients with intermediate- and poor-risk prognostic factors and across all randomized patients.
  • DOR: Median DOR was 82.8 months for patients treated with Opdivo plus Yervoy compared to 19.8 months with sunitinib.
  • ORR: ORR benefits were maintained with Opdivo plus Yervoy compared to sunitinib (42% vs. 27%).
  • DOR: For patients treated with Opdivo plus Yervoy, median DOR was 76.2 months compared to 25.1 months with sunitinib.

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

Retrieved on: 
Monday, January 22, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Bristol Myers Squibb, Exelixis, Checkmate, Patient, Progression-free survival, OS, Partnership, RCC, ASCO, Survival, Society, Risk, Metastasis, PFS, Abstract, Safety, Liver, Confidence interval, GU, BMY, Sunitinib, IMDC, Pharmaceutical industry

Superior overall survival (OS) was also observed in patients treated with the combination.

Key Points: 
  • Superior overall survival (OS) was also observed in patients treated with the combination.
  • ORR (secondary endpoint): The combination regimen showed durable response improvements, doubling the ORR compared to sunitinib (55.7% vs. 27.7%, respectively).
  • ORR: In patients with intermediate-/ poor-risk, ORR was more than doubled at 52.6% with Opdivo and CABOMETYX vs. 23.0% with sunitinib.
  • In those with favorable risk profiles, the number of patients who achieved CR was doubled (16.2% vs. 8.3%) with the combination regimen.

Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers

Retrieved on: 
Wednesday, January 17, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Bristol Myers Squibb, Checkmate, Patient, Research, Drug development, RCC, ASCO, Survival, Ipilimumab, Society, Cancer, Immunotherapy, Safety, BMY, LDD, Sunitinib, Pharmacokinetics, Pharmaceutical industry

Data from 14 company-sponsored studies, investigator-sponsored studies and collaborations will be presented at the meeting.

Key Points: 
  • Data from 14 company-sponsored studies, investigator-sponsored studies and collaborations will be presented at the meeting.
  • , executive vice president and chief medical officer, Drug Development, Bristol Myers Squibb.
  • “These results simultaneously showcase the ongoing success of Opdivo-based combinations in metastatic disease and our contributions to the future of cancer treatment and research.
  • These data represent the longest survival benefit vs. sunitinib reported in patients with previously untreated advanced or metastatic RCC.

M&T Realty Capital Corporation Appoints New CEO and Announces Other Organizational Changes

Retrieved on: 
Tuesday, January 23, 2024
M&T Bank, Life company, Commercial property, Partnership, RCC, CRE, Fannie Mae, Freddie Mac, Investment, Growth, Management

BALTIMORE, Jan. 23, 2024 /PRNewswire/ -- M&T Realty Capital Corporation (M&T RCC), a wholly-owned subsidiary of M&T Bank specializing in providing competitive financing nationwide for multifamily properties, commercial income properties, healthcare facilities, and other property types, announces a series of organizational changes designed to position the business for continued growth and expansion. Michael Edelman, currently serving as President, will succeed current CEO Michael Berman, who will transition to the role of Executive Advisor. Both executives will continue to report to Tim Gallagher, M&T Bank Head of Commercial Real Estate, and Berman will remain a member of M&T RCC's board.

Key Points: 
  • Michael Edelman, currently serving as President, will succeed current CEO Michael Berman, who will transition to the role of Executive Advisor.
  • "Michael Edelman's experience and leadership will be instrumental in driving our initiatives within M&T RCC," said Gallagher.
  • "I am honored to lead this team as we expand access to capital markets and grow our strategic partnerships," said Edelman.
  • For more information on M&T RCC, please visit the M&T Realty Capital Corporation website .